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Regulation of Natural Killer 
Cell Function by STAT3
Nicholas A. Cacalano*
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Natural killer (NK) cells, key members of a distinct hematopoietic lineage, innate lym-
phoid cells, are not only critical effectors that mediate cytotoxicity toward tumor and 
virally infected cells but also regulate inflammation, antigen presentation, and the adap-
tive immune response. It has been shown that NK cells can regulate the development 
and activation of many other components of the immune response, such as dendritic 
cells, which in turn, modulate the function of NK cells in multiple synergistic feed back 
loops driven by cell–cell contact, and the secretion of cytokines and chemokines that 
control effector function and migration of cells to sites of immune activation. The signal 
transducer and activator of transcription (STAT)-3 is involved in driving almost all of the 
pathways that control NK cytolytic activity as well as the reciprocal regulatory interactions 
between NK cells and other components of the immune system. In the context of tumor 
immunology, NK cells are a first line of defense that eliminates pre-cancerous and trans-
formed cells early in the process of carcinogenesis, through a mechanism of “immune 
surveillance.” Even after tumors become established, NK cells are critical components 
of anticancer immunity: dysfunctional NK cells are often found in the peripheral blood of 
cancer patients, and the lack of NK cells in the tumor microenvironment often correlates 
to poor prognosis. The pathways and soluble factors activated in tumor-associated NK 
cells, cancer cells, and regulatory myeloid cells, which determine the outcome of cancer 
immunity, are all critically regulated by STAT3. Using the tumor microenvironment as a 
paradigm, we present here an overview of the research that has revealed fundamental 
mechanisms through which STAT3 regulates all aspects of NK cell biology, including 
NK development, activation, target cell killing, and fine tuning of the innate and adaptive 
immune responses.
Keywords: signal transducer and activator of transcription, STAT3 transcription factor, natural killer cells, 
chemokines, cytokines, cancer immunology
iNTRODUCTiON
Natural killer (NK) cells are a critical component of the innate immune response: a first line of defense 
to protect the host against viral infection and the expansion of cancerous cells. Direct cytolytic 
activity against infected or transformed cells, on the basis of altered or absent MHC class I molecules 
(“missing self ”), is only one of a number of functions performed by NK cells: they are also critical 
regulatory cells that interact with and modulate the activity of other components of the immune 
system, such as dendritic cells (DCs), monocytes/macrophages, endothelial cells, and T  lympho-
cytes. Such regulatory functions are mediated through direct cell–cell interactions as well as via 
2Cacalano NK Cells and STAT3
Frontiers in Immunology | www.frontiersin.org April 2016 | Volume 7 | Article 128
the secretion of immunomodulatory cytokines, which can edit 
and shape the repertoire of antigen-presenting cells (APCs) and 
impact the balance of T cell subsets during an adaptive immune 
response. As a result of this myriad of interactions, NK cells are 
key regulators of the inflammatory response and have emerged 
as important members of the innate lymphoid cell (ILC) family, 
unique lineages of immunomodulatory cells that develop from a 
distinct compartment within the common lymphoid progenitor 
population (1, 2).
Evasion of the immune system is one of the classic hallmarks 
of cancer (3, 4). Tumor cells rapidly evolve to become moving 
targets by modulating the expression of immunogenic proteins 
on their surfaces and by producing a host of soluble factors that 
repress both innate and adaptive immune responses. The critical 
role played by host defenses in tumor rejection is underscored 
by studies in both murine disease and gene knockout models of 
immune function as well as findings in human cancer patients. 
Specifically, the role of NK cells in early detection (immune 
surveillance) and elimination of cancerous cells has been demon-
strated in many animal models, in which selective deletion of NK 
cells leads to the spontaneous development of cancer or failure 
to reject implanted tumor cells (5–8). Likewise, NK cells isolated 
from human cancer patients often display grossly defective 
surface marker profile, cytolytic activity, and cytokine produc-
tion (9–19). Clinically, the critical role of antitumor immunity 
has been validated by marked advances in cancer therapy, which 
employ antibodies that target inhibitory immune checkpoints via 
the CD28–CTLA-4 and PD-1–PD-L1 ligand receptor systems. 
These novel therapies potentiate antitumor immunity mediated 
through CD8+ T cells as well as NK cells and have resulted in 
remarkably effective, durable antitumor immune responses 
(20–26). Like immune checkpoint inhibitors, therapeutics that 
target kinases and transcription factors also show great promise 
as cancer treatments by targeting both the tumor cells as well as 
components of host immunity. Mechanistically, the molecular 
basis for NK cell dysfunction in cancer patients is a highly com-
plex phenomenon that integrates both direct effects on the NK 
cells as well as a range of cell–cell interactions and soluble factors 
that regulate NK activity. NK cells have become an attractive 
target for immunotherapy strategies as they are known to mediate 
direct tumor killing as well as exert a critical “helper” function for 
adaptive immune responses (27–30).
Unfortunately, therapeutic efforts to potentiate NK-mediated 
killing of tumor cells have met with little success. Several 
approaches, involving both in vivo and ex vivo methods to stimu-
late antitumor NK activity have been disappointing, largely due 
to (1) molecular evolution of tumors to promote an immunosup-
pressive microenvironment and (2) the complexity of NK biology 
and its multiple functions in both innate and adaptive immunity. 
NK cells are not just tumoricidal lytic machines, and their pro-
found effects on targeting virus-infected cells, cancer stem cells, 
cytokine and chemokine regulation, and the differentiation of 
normal and cancerous tissue are only now being fully appreciated.
Specific subpopulations of NK cells, generally distinguished 
by a CD56bright/CD16− surface profile secrete critical cytokines 
that can promote the differentiation of normal and transformed 
tissues, which also impacts antitumor immunity and cancer 
progression (31). This small sublineage of NK cells can be found 
in the periphery and represents about 10% of the peripheral NK 
cells, but they can also be induced following the interaction with 
sensitive target cells in a process known as “split anergy” (32–38). 
Thus, NK cells are not only cytotoxic cancer killers but also drive 
activation and maturation of DCs and T cells, and can induce the 
differentiation of normal and cancerous stem cells through the 
secretion of cytokines such as IFN-γ. The finding that cancer stem 
cells are resistant to chemotherapy and radiation, but are highly 
sensitive to NK-mediated cytolysis, has suggested that NK cells 
can be manipulated to target this key population of cells in vivo, 
either by direct NK-mediated killing or by cytokine-driven 
differentiation to a population that no longer has self-renewal 
capacity. A key to reprograming NK cells to effectively kill tumors 
or induce the differentiation of cancer stem cells, however, criti-
cally depends upon our understanding at the molecular level how 
cancers and the tumor microenvironment repress host anticancer 
immunity.
Here, we review current advances in the understanding 
of how the ubiquitously expressed transcription factor signal 
transducer and activator of transcription (STAT)-3 regulates NK 
cell biology at multiple levels, including activation of cytolytic 
function, cytokine-mediated effects, and interactions with other 
components of the immune system. STAT3 is known to limit all 
aspects of the NK response, but in this review, we focus on the 
effects of STAT3 in the context of immune surveillance of cancer 
and modulation of NK activity in the tumor microenvironment.
Signal transducer and activator of transcription-3 is a down-
stream effector of multiple cytokines and growth factors that 
modulate NK cell activity and also drives tumorigenesis and 
resistance of cancer cells to therapy. It is becoming clear that any 
efforts to block STAT3 activity in cancer cells are likely to have 
synergistic and/or deleterious off-target effects on host immune 
responses mediated through NK cells. It is thus critical to under-
stand the effects of STAT3 signaling on NK activity in order to 
apply STAT3-targeted therapies in the most effective way.
ACTivATiON OF STAT3: THe Jak/STAT 
PATHwAY
Signal transducer and activator of transcription-3 is part of a fam-
ily of cytokine and growth factor-activated transcription factors, 
which includes STAT1, STAT2, STAT4, STAT5a/b, and STAT6, 
which are signaling proteins, targets of phosphorylation by Jak 
and receptor tyrosine kinases (RTKs), as well as transcription 
factors whose effects on gene expression profoundly impact the 
immune response, the outcome of viral infections, embryonic 
development, and cancer biology (39–43). STAT3 is activated by a 
wide range of cytokines, in particular those that recognize gp130, 
such as IL-6, IL-11, oncostatin M (OSM), leukemia inhibitory 
factor (LIF), and ciliary neurotrophic factor (CNTF), as well as 
cytokines that engage the common gamma (γc) chain, includ-
ing IL-2, IL-4, IL-7, IL-9, and IL-15. STAT3 is also activated by 
RTKs, such as the epidermal growth factor receptor (EGFR) and 
VEGFR, cytoplasmic kinases, such as Src, as well as some cancer 
therapies, such as ionizing radiation (IR). STAT3 signaling is 
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controlled by several endogenous feedback inhibitors, such as 
the suppressors of cytokine signaling (SOCS), protein inhibitors 
of activated STATs (PIAS), and phosphatases such as SHP-2, 
which dephosphorylates and inactivates cytokine receptor chains 
(39–43).
In the context of tumor biology, STAT3 is often constitutively 
activated and phosphorylated in a wide range of epithelial 
and hematopoietic cancers, largely via paracrine or autocrine 
stimulation by STAT3-activating cytokines and growth factors. 
STAT3 drives tumor cell survival and proliferation, epithelial-
to-mesenchymal transition (EMT), metastasis, and resistance to 
chemotherapy and radiation (44–54). In recent years, previously 
unappreciated critical functions of STAT3 in anticancer immune 
responses have been revealed in both lymphoid and myeloid 
lineages. Thus, STAT3-targeted cancer therapies may have a dual 
function: direct cytostatic or cytotoxic effects on tumor cells and 
stimulation of cancer destruction and clearance by the immune 
system. However, the role of STAT3 in anticancer immunity is 
complex and involves multiple cell lineages, including NK cells. 
STAT3 targeting in tumors may therefore also have unantici-
pated, deleterious effects on tumor immunity. Below, we discuss 
the impact of STAT3 signaling on NK activation and function in 
the tumor microenvironment.
NeGATive ReGULATiON OF NK 
CeLL FUNCTiON BY  
STAT3/iNTRiNSiC FACTORS
Several studies have shown that tumor-infiltrating lymphocytes 
and myeloid cells display constitutive STAT3 phosphorylation, 
including T cells, DCs, neutrophils, macrophages, and NK cells, 
which is often driven by the production of cytokines and growth 
factors by both tumor cells and the infiltrating cells themselves, 
such as IL-6, IL-10, VEGF, and HGF, among others (55). STAT3 
can induce an immunosuppressive tumor microenvironment 
with both direct and indirect effects on NK cells.
To address the role of STAT3 activation in the hematopoietic 
compartment, Kortylewski et  al. used an inducible system to 
delete the STAT3 gene in bone marrow-derived cells (55–58). 
Mice expressing a floxed STAT3 gene in combination with Cre 
driven from the interferon-inducible Mx1 promoter were treated 
with poly I:C to induce interferon and activate STAT3 gene 
deletion in hematopoietic cells. Targeting STAT3 in the bone 
marrow did not have any effect on NK cell development in vivo; 
overall numbers and cytotoxic activity toward standard YAC-1 
lymphoma targets in the knockout mice were comparable to 
WT animals. However, following tumor challenge with the B16 
melanoma cell line, splenic NK cells from STAT3-targeted mice 
displayed enhanced cytolytic activity compared to WT tumor-
bearing mice. Further, subcutaneous growth of B16 melanoma 
cells or the MB49 bladder cancer cell line was virtually abolished 
in STAT3-targeted mice, suggesting that STAT3 exerts a cell-
autonomous immunosuppressive effect in hematopoietic cells in 
the context of an antitumor response.
To exclude the possibility that tumor rejection in STAT3−/− 
mice was due to off-target effects of STAT3 deletion on 
non-hematopoietic tissues, tumor growth studies in lethally 
irradiated WT mice reconstituted with either STAT3+/+ or 
STAT3−/− bone marrow cells were performed, and it was found 
that growth of B16 or MB49 tumors was completely blocked in 
mice reconstituted with STAT3−/− bone marrow cells. Although 
antibody depletion experiments showed that T cells played a criti-
cal role in tumor rejection, NK cells were also involved, as NK 
depletion using anti-asialo-GM1 antibodies partially abrogated 
the effects of a STAT3 small molecule inhibitor (CPA-7) on rejec-
tion of MB49 tumors.
In order to determine the contribution of STAT3 to 
NK-specific antitumor responses, Gotthardt et  al. generated a 
targeted STAT3 deletion specifically in the NK compartment, 
which resulted in increased immunosurveillance in murine 
melanoma and leukemia models (59). In this study, genetic 
ablation of STAT3 was accomplished using STAT3fl/fl mice 
crossed to mice expressing Cre driven from the NKp46 natural 
cytotoxicity receptor (NCR)-1 promoter, which deleted STAT3 
exclusively in NK cells (STAT3fl/fl  ×  Ncr1-iCreTg), sparing 
other hematopoietic lineages. In these mice, NK cell develop-
ment, proliferation, and numbers were normal; NK cells at all 
stages of development are present in numbers similar to WT 
mice, and expression of key NK developmental and functional 
markers, such as NK1.1, NKp46, CD27, CD11b, NKG2D, as well 
as inhibitory receptors, such as LY49A, C, G2, and I, KLRG1 and 
NKG2A, were identical to NK cells from STAT3+/+ animals as 
well as STAT3fl/fl–Mx1-Cre mice. Some differences were noted, 
however, as the numbers of DNAM-1(CD226)+ NK cells were 
increased in STAT3-deficient mice compared to WT. This finding 
is intriguing, as DNAM-1 is a cell surface receptor that mediates 
NK cell cytolytic activity by engaging the CD155 (PVR) and 
CD112 (Nectin-2) ligands on target cells (60–65). In addition, 
the levels of two key mediators of NK-dependent cytotoxicity, 
granzyme B, and perforin were elevated at the protein level in 
STAT3-deficient NK cells, supporting the idea that STAT3 nega-
tively regulates NK activity. In the B16F10 melanoma model, the 
number and size of metastatic lung nodules was greatly reduced 
in mice with STAT3-deficient NK cells, following intravenous 
injection of tumor cells. This was accompanied by an increase in 
the percentage of DNAM-1+ circulating NK cells in the STAT3-
targeted mice and enhanced in vitro cytotoxicity toward B16F10 
tumor targets. B16F10 cells express high levels of the DNAM-1 
ligand CD155 and thus enhanced lysis of B16F10 tumor cells by 
STAT3−/− NK cells was abrogated by treatment with a DNAM-1 
blocking antibody. It is of note that the authors found no evidence 
for enhanced in  vitro cytotoxicity of STAT3-deficient NK cells 
against other targets, such as YAC-1 and Rma cells, which express 
low levels of CD155, suggesting that blocking STAT3 activity in 
NK cells may only increase DNAM-1/CD155-dependent killing. 
STAT3-deficient NK cells were also more efficient at killing leu-
kemic cells in vivo. The size of subcutaneous tumors following 
injection of v-abl-transformed cells was greatly reduced in mice 
with the NK-specific STAT3 knockout. Consistent with the data 
obtained with subcutaneous tumors, it was shown that targeting 
STAT3 also prolonged the survival of mice injected intravenously 
with v-abl-transformed cells or infected with a v-abl-encoding 
retrovirus.
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STAT3-DePeNDeNT eXTRiNSiC FACTORS 
THAT ReGULATe NK ReSPONSeS 
iN CANCeR
Intrinsically, STAT3 activation in NK cells often appears to have a 
negative regulatory role, as deletion of STAT3 in the NK compart-
ment generally results in improved antitumor immunity. However, 
STAT3 activation in tumor cells, as well as in other components 
of the immune response, can provide feedback regulation of 
NK cells in an indirect manner as well. The antitumor activity 
and cytokine profile of NK cells depends on a complex interplay 
among activating and inhibitory cell surface receptors as well as 
a cocktail of soluble factors. The integration of multiple signals 
regulates the migration of NK cells to the tumor microenviron-
ment, NK-mediated recognition of target cells, and downstream 
signaling that controls lytic and helper functions. STAT3 has been 
shown to play a role in all of these processes.
eFFeCTS OF STAT3 ACTivATiON 
iN TUMOR CeLLS
Tumor cells often constitutively produce survival or growth 
factors that enhance tumorigenesis, resistance to therapy, EMT, 
and metastasis (47, 57, 58, 66). Activated STAT3 in tumor cells 
impacts anticancer immunity as well, due to its ability to regulate 
cytokine and chemokine expression by the tumor as well as the 
expression of growth factors and surface markers on infiltrating 
immune cells. It has been known for some time that constitutive 
STAT3 activation in tumor cells can regulate their susceptibil-
ity to NK-mediated cytolysis and the infiltration and migration 
of NK cells within the tumor microenvironment. Constitutive 
STAT3 phosphorylation in tumor cells is usually driven by the 
overproduction of key cytokines and growth factors, such as IL-6, 
IL-10, EGF, HGF, Her2/Neu, and VEGF, or their receptors, as well 
as aberrantly activated cytoplasmic kinases, such as Src, among 
others (57). STAT3 activation in tumor cells can regulate their 
sensitivity to NK-mediated killing by altering the expression of 
NK-activating ligands on the cell surface. In addition, STAT3-
driven cytokine expression in tumors induces the secretion of 
immunosuppressive cytokines and represses proinflammatory 
cytokine expression, leading toward a dampening of immune 
responses in the tumor microenvironment. The relationship 
between STAT3 activation in tumor cells and components of 
the innate and adaptive immune responses is complex and 
multifactorial.
eFFeCTS OF STAT3 ACTivATiON ON 
MiGRATiON OF NK CeLLS TO THe 
TUMOR MiCROeNviRONMeNT
A key proximal event in antitumor immunity is the migration 
of lymphoid and myeloid cells to the tumor microenvironment. 
NK cells depend on chemotactic factors secreted by tumor cells, 
stroma, and other lymphoid and myeloid cells to reach the site of 
action. While proinflammatory signaling promotes the migration 
of NK cells to the microenvironment, continued proinflammatory 
“costimulatory” signals trigger NK-mediated cytokine production 
and lytic function. Major factors that control NK cell migration 
to the tumor microenvironment are chemokines and cytokines. 
NK cells express a range of receptors for soluble factors and thus 
can respond to a number of chemotactic factors, such as TNF-α, 
IL-12, RANTES, macrophage chemotactic protein (MCP)2–3, 
IL-2, MIP1alpha, IL-8, CXCL9, CXCL12, CCL2 (MCP-1), CCL3, 
CX3CL1 (fractalkine), CXCL10, CXCL12, CCL21 (SLC), and 
CCL19 (ELC) (67–71). Dysregulated NK migration to the tumor 
microenvironment has been suggested by studies that found low 
numbers of NK cells associated with tumors in colorectal cancer 
(72). Further, experimental models of cancer have shown that 
gene therapy with CCL2 and CX3CL1/fractalkine can stimulate 
tumor rejection by increased infiltration and activation of NK 
cells (73–76).
Burdelya et  al. demonstrated that several NK chemotactic 
factors secreted by tumor cells are regulated by STAT3 in the 
B16 and K1735 murine melanoma models (77). It was shown 
that increased STAT3 activity of K1735 subclones correlated to 
the decreased lymphocyte infiltration of subcutaneous tumors. 
Treatment of tumor cell lines with a platinum-containing STAT3 
inhibitor (CPA-7) or expression of dominant-negative STAT3 
(STAT3β) splice variant resulted in increased secretion of chem-
oattractants, such as RANTES, IFN-γ-inducible protein (IP-10), 
MCP-1, MIP-2, and T cell activation (TCA)-3. In vivo alteration 
of the cytokine and chemokine profile induced migration of 
T cells, NK cells, neutrophils, and macrophages to the tumor 
microenvironment.
Similarly, Ihara et al. demonstrated similar effects of STAT3 
targeting in a carcinogen-driven model of non-small cell lung 
carcinoma (NSCLC) (78). Using a lung-specific, tetracycline-
inducible Cre-lox system to delete STAT3, it was found that 
the growth of urethane-induced tumors in the lungs of STAT3-
targeted mice was significantly reduced relative to tumors gen-
erated in WT mice. Cell autonomous and non-immune effects 
of STAT3 deletion in tumor cells were excluded, as markers of 
proliferation, angiogenesis, and apoptosis were similar in tumors 
from WT or STAT3−/− mice. In contrast, numbers of lymphoid 
and myeloid cells in bronchoalveolar lavage fluid were increased 
in the STAT3−/− mice, as were the levels of proinflammatory 
cytokines such as IFN-γ, TNF-α, and IL-6. Microarray analysis 
of the tumors revealed that targeting STAT3 increased the 
expression of multiple chemokines, such as CCL2, CCL9, CCL12, 
CCL17, and CCL21c, and induced downregulation of MHC class 
I molecules H2-D1 and H2-K1 in the tumor cells. These results 
indicated that STAT3 inhibition can increase NK cell migration to 
the tumor microenvironment and enhance tumor cell sensitivity 
to NK-mediated lysis. We have recently shown that knock down 
of key proteins in tumor cells and non-transformed healthy cells 
drives dedifferentiation of tumors and results in the activation of 
NK cell function (37).
On the other hand, some studies have shown that STAT3 
can enhance NK-mediated immunosurveillance, specifically 
in a model of BCR/Abl-dependent leukemia. Putz et  al. 
measured subcutaneous tumor formation in bone marrow 
cells transformed by BCR/Ablp185 or v-Ablp160 (79). STAT3 
was targeted by interferon treatment of STAT3fl/fl–Mx1-Cre 
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bone marrow cells or by transfecting with a STAT3-specific 
shRNA lentiviral construct. STAT3-targeted tumors grew 
larger than WT tumors, with a more invasive phenotype and a 
higher mitotic index. Cytokine profiling revealed lower levels 
of proinflammatory mediators IL-6, IFN-γ, IL-17, and CCL5 
produced by STAT3-deficient tumors relative to WT controls. 
Numbers of infiltrating NK cells, as well as CD4+ and CD8+ 
T cells, were significantly reduced in the tumor microenvi-
ronment, with no change in the numbers of Gr1+/CD11b+ 
MDSCs. STAT3-targeted tumor cells were more resistant to 
lysis by purified primary NK cells in  vitro, and the growth 
differences between STAT3-targeted and WT tumors in vivo 
were abrogated in mice lacking NK cells. This study supports 
previous work implicating NK cells as the major lymphoid 
population responsible for eradication of BCR/Abl-driven 
leukemias and suggests that STAT3-targeting strategies may 
severely impair NK-mediated antitumor immune responses 
in BCR/Abl leukemias. These conflicting findings indicate 
that STAT3-targeting strategies in cancer can result in either 
enhancement or inhibition of anticancer immunity, depend-
ing on context and tumor type.
ReGULATiON OF NK ReCOGNiTiON 
MOLeCULeS AND iMMUNe CHeCKPOiNT 
ReCePTORS BY STAT3
NKG2D/MiCA
A critical mechanism of NK-mediated recognition of target cells 
is via the NKG2D NK-activating receptor (80–90). NKG2D is a 
transmembrane receptor expressed on the surface of NK cells, 
which physically associates with the DAP10 signaling chain in 
humans. The fully functional complex is a hexamer, with one 
NKG2D homodimer physically associated with two Dap10 
homodimers. Recognition of NKG2D ligands, which include 
the MHC class I polypeptide-related chain (MIC)A, MICB, and 
members of the Rae-1, ULBP, Mult1, and H60 families, induces 
phosphorylation of a Y–X–X–M motif on the cytoplasmic tail of 
DAP10, and activates NK degranulation and killing of target cells. 
NKG2D engagement triggers both PI-3 kinase and MAPK signal-
ing pathways and can override inhibitory signals via MHC class I 
recognition by killer inhibitory receptors (KIRs). The importance 
of NKG2D-mediated elimination of tumor cells is underscored 
by findings in NKG2D gene-targeted mice. In animals lacking 
NKG2D receptors, NK cell development is normal, but immune 
surveillance of epithelial and lymphoid cancers is defective (91).
The MICA NKG2D ligand is a stress-induced cell surface 
molecule that is upregulated in response to genotoxic stimuli, 
such as chemotherapy or radiation, as well as chromatin disrup-
tion and heat shock (89–91). The importance of MICA/NKG2D 
engagement in the control of cancer has been demonstrated by 
several studies showing that increased soluble MICA protein in 
the serum of cancer patients leads to downregulation of NKG2D 
on NK cells and correlates to poor prognosis (92). STAT3 has 
been shown to regulate NK lytic activity via transcriptional 
effects on NK recognition receptors and activating NK ligands 
on tumor cells.
Bedel et  al. demonstrated that pharmacologic or genetic 
inhibition of STAT3 in a human colorectal cell line (HT29) 
resulted in increased NK cell degranulation (CD107a expres-
sion) and IFN-γ production in an in  vitro coculture assay 
(93). HT29 is highly resistant to NK-mediated lysis, which 
correlates to high levels of constitutive STAT3 phosphorylation 
and protein expression relative to NK-sensitive human tumors. 
Targeting STAT3 in HT29 with siRNA increased IFN-γ produc-
tion of freshly isolated human NK cells when cocultured with 
HT29. Pretreatment of cocultures with anti-NKG2D antibody 
inhibited IFN-γ secretion and NK-mediated cytotoxicity of 
STAT3-targeted HT29. The effect of anti-NKG2D antibodies 
was attributed to increased expression of NKG2D ligands MICA 
and ULBP2 in STAT3-deficient HT29 cells; MICA expression 
was increased approximately ninefold, following treatment 
HT29 with a pharmacologic inhibitor of STAT3 (STA21). STAT3 
inhibition increased MICA expression in human GBM and 
breast cancer cell lines as well, and STAT3 was shown to bind 
directly to a putative STAT-binding site in the MICA promoter. 
Pharmacologic STAT3 inhibition increased MICA promoter 
activity, and expression of a constitutively active STAT3 mutant 
(STAT3C) blocked MICA expression in a human stromal cell 
line, demonstrating that STAT3 acts as a MICA transcriptional 
repressor in this system.
Likewise, Fionda et al. demonstrated a molecular link between 
glycogen synthase kinase (GSK)-3, STAT3, and MICA regulation 
in multiple myeloma (MM) (94). It was found that pharmaco-
logic inhibition of GSK-3 downregulated MICA expression and 
increased the sensitivity of human MM cell lines to NK-mediated 
cytotoxicity. The effect of GSK-3 inhibition was dependent on 
downregulation of STAT3 phosphorylation and reduced STAT3 
binding to the MICA promoter. It was also shown that expres-
sion of a constitutively active STAT3 mutant repressed MICA 
expression in MM cell lines and reversed the effect of GSK-3 
inhibitors in MM.
In contrast, some STAT3-activating stimuli can increase 
NKG2D expression on NK cells in both mice and humans. Zhu 
et  al. have shown that IL-10 and IL-21 can induce high levels 
of NKG2D, DAP10, and DAP12 expression on the surface of 
primary human NK cells, and small-molecule STAT3 inhibitors 
downregulated NKG2D expression on primary human NK cells 
from healthy donors (95). Likewise, STAT3-deficient NK cells 
from gene-targeted mice displayed lower NKG2D surface expres-
sion than WT controls. The in vivo relevance of STAT3-mediated 
NKG2D regulation was supported by the finding that NK cells 
from patients with inactivating STAT3 mutations in conditions, 
such as hyper IgE syndrome (HIES), displayed lower NKG2D 
surface expression relative to normal NKs.
In agreement with these studies, IL-21 was shown to augment 
NKG2D-dependent killing in several murine tumor models (96). 
Interleukin-21 pretreatment significantly extended survival of 
mice in a lymphoma model and blocked tumor metastasis in 
murine models of breast, lung, and prostate cancer. The protec-
tive effects of IL-21 were reversed upon treatment of mice with 
anti-NKG2D antibodies or NK-depleting anti-NK1.1 antibod-
ies. These studies suggest that IL-21-driven STAT3 activation 
regulates NKG2D expression, although other IL-21-dependent 
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pathways, such as ERK MAP kinase and PI-3 kinase/Akt, are 
likely to also play a role.
On the other hand, Burgess et al. have shown that IL-21 can 
inhibit the expression of NKG2D and the adapter/signaling 
protein DAP10 on IL-2-activated primary human NK cells (97). 
Interestingly, IL-21 inhibited DAP10 gene promoter activity and 
reduced surface expression of NKG2D but increased the NK 
NCR NKp30 and 2B4, suggesting that IL-21 can reprogram NK 
specificity by editing the recognition receptor repertoire on the 
cell surface. The different effects of IL-21 in these studies might 
be explained by the complex interplay between STAT molecules. 
Interleukin-21 can activate both STAT1 and STAT3, which exert 
opposing effects in T cells, in particular on the expression of dif-
ferent STAT-dependent genes such as IFN-γ. Thus, it is possible 
that whether STAT3 has a positive or negative effect on NKG2D 
or DAP-10 expression depends on the STAT1/STAT3 balance at 
the time of stimulation (98).
Taken together, STAT3 targeting of tumors may promote 
NK-mediated cytotoxicity by increasing MICA expression on 
target cells but can have both positive and negative effects on 
NK-mediated recognition of tumors by modulating the expres-
sion of NK-activating receptors. These conflicting data indicate 
that the role of STAT3 in the regulation of NK ligands and 
receptors likely depends on cellular context, the balance between 
STAT1 and STAT3 activation, method of stimulation, and assay 
conditions used in the studies.
STAT3-MeDiATeD ReGULATiON OF THe 
PD-1/PD-L1 iMMUNe CHeCKPOiNT
The programmed cell death (PD)-1 (CD279)/PD-L1 (B7-H1 
and CD274) immune checkpoint pathway has been the focus of 
intense investigation and clinical application in the last several 
years. Inducibly expressed on activated T cells, PD-1 is considered 
a marker of lymphoid cell “exhaustion” or chronic stimulation. 
Engagement of PD-1 on T cells via its ligands PD-L1 or PD-L2 
on the surface of lymphoid cells, macrophages, IFN-stimulated 
epithelial cells, DCs, or tumor cells blocks T cell receptor (TCR) 
signaling on cytolytic CD8+ cells via the recruitment of the 
SHP-2 phosphatase and dephosphorylation of the TCR complex 
(99–106). Tumor cells from various tissues upregulate PD-L1 
expression, which inhibits T cell-mediated antitumor immunity. 
Much is known of PD-1 signaling in T cells, and remarkable, 
durable antitumor immune responses have been achieved in 
melanoma and lung cancer using therapeutic antibodies that 
block PD-1/PD-L1 engagement (107–115). PD-1/PD-L1 block-
ade, as a monotherapy or in combination with IR and epigenetic 
targeting, has shown great promise as a novel emerging cancer 
treatment and is currently being tested clinically for several other 
solid and hematopoietic cancers (116–119). Although PD-1 is 
known to be upregulated on NK cells, its role in the regulation of 
NK-mediated immune surveillance and tumor killing is poorly 
understood.
At the molecular level, novel high-resolution, high-throughput 
imaging studies have demonstrated that PD-1 on the surface 
of NK cells is situated within the immunologic synapse upon 
engagement with a target cell. This work provides evidence 
that PD-1 is physically associated with the cytolytic signaling 
machinery, with access to NK activating receptors and provides 
evidence that the composition of the NK immunologic synapse 
can promote PD-1-mediated dephosphorylation of NK recogni-
tion structures and blunt lysis of tumor cells (120).
Marzec et al. have demonstrated that NPM/ALK-transformed 
T cell lymphoma cells escape immune destruction via induction 
of PD-L1. PD-L1 expression was STAT3-dependent and STAT3 
bound directly to the PD-L1 promoter, which has four putative 
STAT-binding sites (121). Further, Benson et  al. have shown 
that NK cells from MM patients express PD-1 at a much higher 
level than NK cells from normal donors (122). The functional 
significance of PD-1 expression was demonstrated by increased 
NK-mediated lysis of autologous MM cells following treatment 
with an anti-PD-L1-blocking antibody (CT-011). The authors 
also suggest that the immunomodulatory effects of the thera-
peutic lenalidomide can, in part, be explained by its ability to 
downregulate PD-L1 expression on primary MM cells, leading 
to increased NK-mediated lysis and synergy with CT-011. Thus, 
in at least some tumor models, NK-mediated immune surveil-
lance can be inhibited by STAT3-dependent increases in PD-L1 
expression. It is also of interest to note that most highly differenti-
ated tumors express PD-L1 and are found to be resistant to NK 
cell-mediated cytotoxicity (37). Figure 1 and Table 1 summarize 
the direct effects of STAT3 activation on the expression of NK 
activating receptors as well as inhibition of cytotoxicity and 
migration by downregulation of NK ligands and chemotactic 
factors in tumor cells.
eFFeCTS OF STAT3 ACTivATiON ON 
CeLL–CeLL COMMUNiCATiON wiTHiN 
THe TUMOR MiCROeNviRONMeNT
Perhaps the most important (and complex) role for STAT3 in NK 
function is as a regulator of cell–cell communication within the 
tumor microenvironment. STAT3 controls numerous indirect 
effects on NKs through cytokine secretion by tumor cells, devel-
opmental regulation of DCs, as well as chemokine and cytokine 
production by DCs, macrophages, and MDSCs, all of which exert 
feedback controls on NK cell migration, activation, and lytic 
activity (4, 123–129).
Mutually activating, “helper” interactions between NK cells 
and DCs have been shown to promote the functional capabili-
ties of both cell types as well as inducing the differentiation of 
CD4+ and CD8+ T cells, while downregulating immunosuppres-
sive lineages such as Tregs and myeloid-derived suppressor cells 
(MDSCs) (124, 130–132). Interleukin-18, produced by epithelial 
cells and macrophages, “primes” NKs responses to DC-derived 
IL-12 and activates IFN-γ production. Reciprocally, activated 
NKs produce potent chemoattractants for immature DCs, 
CCL3, and CCL4, which induce DC migration to the tumor site 
and drive DC maturation. Interferon gamma and TNF-α pro-
duced by activated NK cells can induce polarization of DCs, and 
NKs also target and kill tolerogenic, immature autologous DCs, 
increasing the ratio of mature:immature DCs. Thus, NK cells can 
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FiGURe 1 | effects of cancer cell-derived factors that drive STAT3 activation in tumors, NK cells, and myeloid-derived suppressor cells (MDSCs). 
Tumors produce multiple soluble factors that activate STAT3 in cells of the tumor microenvironment. Among the direct effects of STAT3 activation in NK cells include 
blunting the expression of key NK activating receptors DNAM-1 NKp30, NKp44, and NKG2D, and inhibition of perforin A and granzyme B expression, which blunts 
cytotoxic activity. STAT3 activation in tumor cells represses the expression of NK chemotactic factors, which reduces the recruitment of NK cells to the tumor 
microenvironment, and blunts the expression of NKG2D ligands MICA and ULBP1/2/3, which renders the cells resistant to NK-mediated killing. STAT3 has also 
been shown to increase the levels of PD-L1, which can engage PD-1 expressed on NK cells and inhibit cytotoxic responses. Finally, IDO and TGF-beta produced by 
both tumor cells and MDSCs block NK cell development, proliferation, and activation.
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not only provide helper function to DCs but can also help shape 
the DC repertoire toward an immunogenic phenotype through 
a mechanism known as “dendritic cell editing” (28, 125, 133, 
134). Inhibition of NK cell function via STAT3 activation can 
therefore skew the DC lineage toward an immature, immuno-
suppressive phenotype. Likewise, disruption of DC maturation 
or function can impair NK cell-mediated killing and cytokine 
production. On the other end of the spectrum, MDSCs can 
negatively regulate NK cell function through multiple secreted 
factors, some of which are, at least in part, STAT3 dependent 
(Figure 2).
STAT3 ACTivATiON iN TUMOR CeLLS 
ReGULATeS DC FUNCTiON 
AND MATURATiON
Several studies have shown that STAT3 activation can disrupt 
interactions between immunocompetent cells in the tumor 
microenvironment and induce an immunosuppressive milieu. 
Blocking STAT3 activation in murine tumor models alters the 
cytokine profile of tumor cells and tumor-infiltrating hemat-
opoietic cells, and re-establishes proinflammatory, tumoricidal 
activity.
Early studies in cancer patients and murine tumor models 
revealed that DCs from the tumor microenvironment were defec-
tive in antigen presentation. In particular, it was shown that DCs 
grown from bone marrow precursors of tumor-bearing mice were 
efficient APCs, but mature splenic DCs from the same mice were 
defective, suggesting that tumors produced soluble factors that 
inhibited DC development (135–141). Likewise, several groups 
found reduced numbers of peripheral DCs in patients with can-
cers of the kidney, skin, and colon. DCs from cancer patients and 
animal models were defective in antigen presentation function 
and failed to effectively induce the B7-1 and B7-2 costimulatory 
molecules (142, 143). Cancer patients were also shown to produce 
increased numbers of LIN−/HLA-DR− immature myeloid cells in 
the peripheral blood, indicating defective myelopoiesis induced 
by tumor factors.
Gabrilovich et al. demonstrated that growth factors produced 
by tumor cells, in particular vascular endothelial growth factor 
(VEGF), IL-6, IL-10, macrophage colony stimulating factor 
(M-CSF), and granulocyte–macrophage colony stimulating fac-
tor (GM-CSF), induced severe developmental defects in DCs as 
well as general dysfunction of myelopoiesis (144–147), and later 
studies showed that these effects can be traced to STAT3 activa-
tion in myeloid progenitors. Supernatants from human breast 
and colon adenocarcinoma cell lines impaired the differentiation 
of human CD34+ hematopoietic stem cells (HSCs) to functional 
DCs but did not affect the total number of multipotent stem 
cells or the antigen presentation function of mature DCs from 
the periphery, demonstrating a highly specific effect of secreted 
factors on DC differentiation. The inhibitory effect of the tumor 
supernatants was reversed by preincubation with anti-VEGF 
neutralizing antibodies and partially overcome with blocking 
antibodies specific for M-CSF.
TABLe 1 | Summary of STAT3-mediated regulation of NK function.
effect of STAT3 on molecular profile Biological effects Reference
Direct effects on NK cells
Decreased NKG2D and DAP10 expression Reduced recognition of target cells through NKG2D ligands, reduced signaling 
via DAP10 engagement, and decreased cytotoxicity
(97)
Decreased expression of DNAM-1(CD226)+ Impaired cytotoxicity via recognition of DNAM-1 ligands Nectin-2 (CD112) and 
poliovirus receptor (PVR and CD155) on target cells
(59)
Decreased expression of granzyme B and perforin A Impaired cytotoxic activity and granzyme B-driven apoptosis of target cells (59, 193)
Decreased production of IFN-γ and TNF-α Impaired NK activation, maturation, and cytotoxic activity, reduced DC editing, 
and impaired NK-induced cell differentiation
(32, 33, 37, 93)
Direct effects on tumor cells
Decreased expression of NKG2D ligands MICA, 
ULBP1, ULBP2, and ULBP3
Impaired NKG2-mediated cytolysis via recognition of MICA and ULBP1–3 (93, 94, 193)
Increased PD-L1 expression Impaired NK-mediated cytotoxicity due to engagement of the inhibitory 
checkpoint molecule PD-1
(121)
Decreased expression of NK chemotactic factors 
RANTES, IP-10, MCP-1 (CCL2), MIP-2, TCA-3, CCL9, 
CCL12, and CCL17
Inhibition of NK migration to the tumor microenvironment (77, 78, 150)
Increased MHC class I expression Inhibition of NK-mediated cytotoxicity due to engagement of killer inhibitory 
receptors (KIRs) by MHC class I molecules
(78)
effects on cell–cell communication
Increased production of IL-23 by macrophages Inhibition of IL-12-induced IFN-γ production by NK cells, inhibition of  
IFN-γ-induced NK maturation and activation, and inhibition of antiviral activity
(151)
IDO expression by tumor cells and MDSCs Reduced expression of cytotoxicity receptors DNAM-1 NKp30, NKp44, and 
NKG2D on NK cells; inhibition of NK-mediated cytotoxicity
(168–171)
Decreased expression of CD40, MHC class II, and 
IL-12 by DCs
Inhibition of NK cell proliferation, activation, and IFN-γ production (150)
TGF-β production by tumor cells and MDSCs Inhibition of NK-mediated IFN-γ production (183–190)
Inhibition of RANTES expression by macrophages Inhibition of NK migration (150)
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Nefedova et al. subsequently demonstrated that conditioned 
medium from the murine CT26 colon carcinoma or C3 sarcoma 
cell lines could trigger Jak2/STAT3 signaling in hematopoietic 
progenitor cells (HPCs) and resulted in the abnormal accumula-
tion of Gr1+/CD11b+ immature myeloid cells in an in vitro DC 
differentiation assay (148, 149). Likewise, CD11c+/IAd+ imma-
ture DCs, differentiated in the presence of tumor supernatants, 
displayed much higher STAT3 DNA binding activity compared 
to control DCs and were impaired in their ability to stimulate 
T cell proliferation in an allogeneic mixed lymphocyte reaction 
(MLR). Expression of a dominant-negative STAT3 mutant in 
HSCs reversed the effects of tumor supernatants. Conversely, 
expression of a constitutively active STAT3 mutant resulted in 
the accumulation of Gr-1+/CD11b+ immature myeloid cells that 
poorly differentiated into DCs in vitro, demonstrating the causa-
tive role of STAT3 in defective DC development.
Wang et al. have shown that in three murine cancer models 
with constitutive STAT3 activation, B16 (melanoma), SCK-1 9 
(breast carcinoma), and CT26 (colon carcinoma), expression of a 
dominant-negative STAT3 variant, STAT3β, or a STAT3-targeting 
siRNA increased the levels of the proinflammatory cytokines 
IFNβ, TNF-α, and IL-6, as well as the chemokines RANTES and 
CXCL10 (IP-10) in the tumor cells, with no effect on IL-4 and 
IL-10 production (150). Furthermore, conditioned media from 
STAT3β-expressing B16 tumor cells induced proinflammatory 
mediators nitric oxide (NO) and RANTES in peritoneal mac-
rophages and TNF-α in neutrophils. STAT3-targeted B16 tumors 
in vivo also contained higher levels of infiltrating macrophages, 
neutrophils, and lymphocytes compared to tumors derived from 
the B16 parental cell line.
Conditioned medium from STAT3-targeted B16 mela-
noma and CT26 colon carcinoma cells also altered the surface 
 phenotype of DCs, inducing higher expression levels of DC acti-
vation and maturation markers IL-12, CD40, and MHC class II 
 molecules. In vivo, STAT3β+ B16 and CT26 tumor cells triggered 
DC activation and enhanced infiltration of tumor-specific CD8+ 
T cells. In reciprocal experiments, constitutive STAT3 activation 
in transformed cells induced the production of secreted factors 
that inhibited DC maturation, reduced the numbers of CD11c+, 
MHC class II+ cells, and blocked IL-12 production in an in vitro 
DC differentiation assay.
The findings from these studies indicate that STAT3 activa-
tion is at the apex of a cascade, beginning in tumor cells, which 
determines the cytokine profile of the cancer and triggers further 
STAT3 activation in lymphoid and myeloid populations within 
the tumor microenvironment, promoting immunosuppression 
and tumor escape. STAT3-driven inhibitory effects on the pro-
duction of chemokines and inflammatory mediators by tumor 
FiGURe 2 | STAT3 regulates reciprocal interactions between NK cells and other components of the immune response. NK cells interact with dendritic 
cells (DCs) in regulatory loops that amplify the activation and function of each cell type. NK cells produce cytokines that drive the differentiation and polarization of 
DCs to mature, fully functional antigen-presenting cells. Further, NK cells produce potent chemotactic factors CCL3 and CCL4, which recruit DCs to the tumor 
microenvironment and can shape the DC repertoire via cytotoxic elimination of tolerogenic, immature DCs. These functions drive the adaptive immune response by 
potentiating DC-mediated activation of T cells. Reciprocally, DCs drive NK cell maturation through the production of IL-12. Tumor cell production of cytokines that 
trigger STAT3 in NK cells and DCs send the antitumor immune response into a tailspin by blocking NK-mediated DC editing and polarization, which inhibits IL-12 
release and further impairs NK cell activation and function. STAT3 activation of tumor-associated macrophages also inhibits the immune response by inducing the 
production of the immunosuppressive cytokine IL-23 and blocking the secretion of NK chemotactic factor RANTES.
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cells, inhibition of DC maturation, and the production of IL-12 
can block NK activity within the tumor microenvironment 
(Figure 2).
STAT3 DeTeRMiNeS THe ReLATive 
ABUNDANCe OF iL-12 AND iL-23 iN THe 
TUMOR MiCROeNviRONMeNT
Signal transducer and activator of transcription-3 signaling has 
been shown to regulate the cytokine balance and functional 
interactions between NKs and other hematopoietic cells in the 
tumor microenvironment. In particular, STAT3 regulates the 
levels of two key cytokines, IL-12 and the procarcinogenic IL-23, 
which are related cytokines that share a common ligand chain 
(IL12p40), as well as a common receptor chain (IL-12Rb1), 
but exert opposing effects on antitumor immunity (151). Both 
cytokines are produced primarily by macrophages and DCs, but 
they differ critically in their signaling properties. Interleukin-12 
is a STAT4 activator, while IL-23 is a potent STAT3 inducer. There 
is also evidence that IL-12 and IL-23 cross inhibit each other 
during an inflammatory response (152, 153). Interleukin-12 is 
a critical cytokine that induces the maturation and functional 
activation of NK cells; it has been shown that NK cell dif-
ferentiation and effector function are defective in IL-12- and 
IL-12 receptor-deficient mice, and patients with IL-12/IL-12R 
mutations are immunodeficient (154–158). In the context of an 
antitumor immune response, administration of recombinant 
IL-12 has antitumor effects, and IL-12 knockout mice were 
found to be more susceptible to ultraviolet light (UV)-induced 
tumors and skin papillomas (159). Conversely, Langowski et al. 
have shown that mice with a targeted deletion of the IL-23p19 
subunit are completely resistant to TPA-induced skin papillomas, 
demonstrating a tumor promoting function for IL-23 (160, 161).
A recent study has shown that STAT3 signaling controls the 
IL-12:IL-23 ratio in the tumor microenvironment (151). When 
subcutaneously grown B16 melanoma tumors were dissociated 
and tumor-associated myeloid cells purified, it was found that 
tumor-infiltrating CD11b+ c-macrophages secreted high levels of 
IL-23, whereas tumor-associated DCs (CD11b+c+) cells produced 
very little IL-23. Conversely, neither macrophages nor DCs within 
the B16 tumor microenvironment secreted significant amounts of 
IL-12. When STAT3 expression was ablated in the hematopoietic 
compartment using the STAT3fl/fl–Mx1-Cre system, the levels 
of macrophage-derived IL-23 was greatly reduced and tumor-
associated DCs secreted increased amounts of IL-12. STAT3 was 
shown to be a direct transcriptional activator of the IL-12p19 
gene, and IL-23 in the tumor microenvironment inhibited IL-12 
production by tumor-associated DCs. STAT3-dependent recipro-
cal regulation of IL-23 and IL-12 was demonstrated in melanoma 
(B16), bladder (MB49), and colon (MB38) cancer models and 
targeting STAT3 in reduced tumor growth in vivo.
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These studies demonstrate that the ability of the immune 
system to reject a tumor depends critically on a delicate balance 
of secreted factors and cell–cell interactions. Altering these 
conditions through aberrant STAT3 activation can establish an 
immunosuppressive circuit between tumor cells and infiltrating 
macrophages, DCs and NK cells, driven by STAT3 activation 
in all three subpopulations. Immunosuppressive reprograming 
of the tumor microenvironment results in a negative feedback 
loop, wherein STAT3 activation in NK cells inhibits direct tumor 
cell cytolysis and DC maturation by inhibiting NK-dependent 
IFN-γ and TNF production and blocking the release of antigenic 
proteins by NK-mediated lysis of tumor targets; STAT3 activa-
tion in the myeloid compartment blocks the production of IL-12 
by DCs and triggers the secretion of IL-23 by tumor-associated 
macrophages, which further impairs NK cell activation and skews 
the DC repertoire toward an immunosuppressive phenotype by 
preventing NK-mediated lysis of immature, tolerogenic DCs. 
Crosstalk between NK cells, macrophages, and DCs has further 
immunosuppressive effects on the adaptive immune response 
by inhibiting the proper activation of CD4+ and CD8+ T cells 
and promoting the infiltration, development, and activation of 
MDSCs and CD4+, FoxP3+ regulatory T cells (TRegs). Thus, a 
STAT3-activating tumor microenvironment, which begins with 
the production of cytokines and growth factors by tumor cells, 
triggers a STAT3 cascade in tumor-infiltrating immune cells that 
has long-range, profound effects on host antitumor immunity that 
allows the cancer to escape detection and destruction (Figure 2).
STAT3-DePeNDeNT ReGULATiON OF 
iNDOLeAMiNe 2,3-DiOXYGeNASe iN 
THe TUMOR MiCROeNviRONMeNT
Myeloid-derived suppressor cells from both humans and mice 
produce indoleamine 2,3-dioxygenase (IDO), which negatively 
regulates the function of both myeloid and lymphoid lineages 
within the tumor microenvironment. IDO catalyzes the rapid 
catabolism of tryptophan to kynurenine, which inhibits prolifera-
tion and effector function of T and NK cells (162–167). Expression 
of IDO in the tumor microenvironment inhibits NK function by 
downregulation of activating NK receptors DNAM-1, NKp30, 
NKp44, and NKG2D, inhibition of IFN-γ production, increased 
IL-4 and IL-13 secretion, and induction of NK cell apoptosis 
(168–171). Strikingly, IDO is also overexpressed by tumor cells, 
as well as tumor-associated fibroblasts, and mesenchymal stem 
cells (MSC); regardless of the source, IDO has been shown to pro-
foundly inhibit NK-mediated cytokine production, expression of 
natural cytolytic receptors (NCRs), and tumor cell cytolysis.
Yu et  al. identified an “immature” subset of MDSCs 
(CD33+CD13+CD14−CD15−), induced from CD33+ pro-
genitors upon coculture with the human breast cancer cell line 
MDA-MB-231, that produced high levels of IDO (172, 173). 
In this MDSC subpopulation, STAT3 was required for NFκB-
inducing kinase (NIK) phosphorylation and activation of the 
non-canonical NFκB signaling pathway, which upregulated 
IDO expression by direct activation of the IDO promoter. A 
Jak/STAT inhibitor, JSI-124 (cucurbitacin I), blocked STAT3 
phosphorylation, NFκB activation, and IDO production by 
MDSCs. In tumor sections from 30 breast cancer patients, the 
percentage of CD33+/pSTAT3+ co-expressing cells was 80, sug-
gesting a critical role for this pathway in driving IDO expression 
in MDSCs associated with primary human breast tumors.
Constitutive, STAT3-dependent IDO expression in drug-
resistant tumor cells has been described by Campia et al. (174). 
Doxorubicin (Dox)-resistant clones of human colon (HT29), lung 
(A549), and leukemia (K562) cell lines, a murine chemoresistant 
breast cancer cell line (JC), and human metastatic mesothelioma 
(HMM) were shown to express high levels of IDO1 and displayed 
enhanced subcutaneous growth in vivo relative to chemosensitive 
parental cell lines. Enhanced tumor growth was blocked by treat-
ment of mice with an IDO1 inhibitor, 5-Br-Brassinin. Expression 
of IDO correlated to enhanced Jak1, STAT1 and STAT3 phospho-
rylation, and the expression of STAT3 targets that induce IDO 
expression, such as IL-6, IL-1β, IL-4, IL-13, CD40L, and TNF-α. 
Interestingly, the expression of PIAS3, an endogenous negative 
feedback inhibitor of STAT3 signaling, was downregulated in 
drug-resistant A549 cells relative to the parental cell line. These 
results suggest that constitutive STAT3 signaling and IDO expres-
sion in drug-resistant tumors may be enhanced by the inactiva-
tion of STAT3-specific feedback controls such as PIAS3.
Other studies have linked STAT3 and the aryl hydrocarbon 
receptor (AHR) to IDO expression in human NSCLC and ovar-
ian cancer (175). Litzenberger demonstrated that IDO can drive 
its own production via an IDO–AHR–IL-6–STAT3 signaling 
pathway. IDO metabolizes tryptophan to kynenurine, which 
binds to the AHR, transactivating target genes such as IL-6. 
Interleukin-6 activates STAT3, which drives IDO transcription, 
sustaining the cycle.
Likewise, Chen et al. have demonstrated that IDO is induced 
in human breast fibroblasts (RMF-EG) following co-incubation 
with COX-2-overexpressing breast cancer cells (176). It was 
shown that COX-2-dependent production of PGE2 in human 
breast cancer cell lines induced IDO, and targeting of the PGE2 
receptor EP4 abrogated IDO induction. Two STAT-binding GAS 
elements were identified in the IDO promoter. STAT3 binding to 
the IDO GAS elements was increased in fibroblasts when cocul-
tured with breast cancer cells, and siRNA targeting of STAT3 
abolished IDO induction by a EP4 agonist.
In summary, there are multiple pathways by which STAT3 
indirectly modulates the function of NK cells, either by the 
production of tumor-derived immunosuppressive factors, such 
as IDO, or by driving the development of immunosuppressive 
myeloid populations, such as MDSCs, which secrete IDO, trans-
forming growth factor (TGF)-β, or other soluble factors that 
block NK development, cytolytic function, or cytokine produc-
tion (Figure 1; Table 1).
ReGULATiON OF NK FUNCTiON BY 
STAT3-iNDUCeD TGF-β PRODUCTiON
Another key regulatory pathway that influences NK cytolytic and 
helper functions involves TGF-β. It has been well documented 
that TGF-β is produced by both tumor cells and tumor- infiltrating 
myeloid cells (177–182). The biological effects of TGF-β in 
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tumorigenesis have been extensively characterized, and it has 
been shown to both inhibit and promote tumor activity, depend-
ing on the context. Tumor cells often escape the growth inhibitory 
effects of TGF-β by converting its signaling to promote invasive, 
metastatic behavior, and can drive EMT. TGF-β regulates the 
immune system on many levels and modulates the function of 
most lymphoid and myeloid lineages.
In the tumor microenvironment, high levels of TGF-β are 
attributed to several mechanisms, including overexpression by 
tumor cells and cancer-associated fibroblasts (CAFs), as well as 
induced expression in tumor-infiltrating MDSCs and regulatory 
T cells (Tregs). Several immunosuppressive TGF-β target genes 
have been identified, including FoxP3, which drives the develop-
ment of Tregs (181, 182).
Transforming growth factor-β impairs NK function by reduc-
ing the expression levels of NK activating receptors NKG2D and 
NKp30, blocking the production of IFN-γ and chemokines, and 
inhibiting NK cell degranulation by impairing release of gran-
zyme A and granzyme B (183–190). More indirectly, TGF-β also 
impairs DC-driven activation of T and NK cells by reducing the 
expression of IL-12, MHC class II molecules, and the costimula-
tory molecules CD80 and CD86 (191).
In several studies, disruption of STAT3 signaling in tumor 
cells was shown to drive down TGF-β expression and potentiate 
NK-mediated killing of tumor targets. Sui et al. demonstrated a 
link between STAT3, TGF-β, and tumor surveillance by NK cells 
in a model of hepatocellular carcinoma (HCC) (192). Treatment 
of two murine HCC cell lines, Hepa1–6 and H22, with a STAT3-
binding site decoy oligonucleotide impaired tumor growth in vivo 
and prolonged survival of animals with subcutaneous tumors. 
Numbers of peripheral NK cells (CD3−/DX5+) and cytotoxic 
function of liver- or spleen-derived lymphocytes against H22 
target cells was increased in mice bearing STAT3-targeted H22 
tumors relative to NK cells from mice injected with the parental 
H22 cell line. Peripheral and tumor-associated NK cells from 
STAT3-targeted tumor-bearing mice also expressed elevated 
levels of NK activation markers NKG2D, CD69, and Fas ligand 
(FasL). Critical involvement of NK cells in tumor rejection was 
demonstrated by showing that STAT3 deletion impaired H22 
growth in nude mice, which lack T cells but have functional 
NK cells. Antibody-mediated depletion experiments in immu-
nocompetent mice showed that the inhibitory effect of STAT3 
targeting was greatly reduced when NK cells were ablated with 
an anti-asialo-GMP antibody, and adoptive transfer of purified 
CD3−/DX5+ NK cells from tumor-bearing mice inhibited H22 
tumor growth and extended survival of recipient mice. The role 
of TGF-β was demonstrated by antibody blocking experiments in 
which anti-IL-10 plus anti-TGF-β antibodies could reproduce the 
effects of STAT3 targeting of H22 cells in in vivo tumor growth 
experiments.
Likewise, Sun et  al. demonstrated a critical link between 
STAT3 blockade and inhibition of TGFβ production in HCC cell 
lines, leading to increased sensitivity to NK-mediated lysis (193). 
Human HCC cells lines Hep2G, H7402, and PLC/PRF/5 were 
more sensitive to killing by human PBMCs and NK cell lines NKL 
or NK-92 when transfected with a STAT3-binding decoy oligonu-
cleotide. A major effect of STAT3 targeting in HCC was increased 
expression of NKG2D ligands ULBP1, ULBP2, and ULBP3, and 
enhanced NK-mediated killing of STAT3-targeted HCC cells was 
partially reversed by treatment with an anti-ULBP3 neutralizing 
antibody.
Further, supernatants from STAT3-targeted HCC cells 
enhanced the cytolytic activity of NK cell lines against HCC 
tumor targets, suggesting that the profile of secreted factors by 
the tumor cells was altered by STAT3 inhibition. Supernatants 
from STAT3-targeted tumor cells increased the expression of 
NK activation markers, such as CD69, NKG2D, Fas ligand, 
granzyme B, perforin, and IFN-γ. Cytokine profiling identi-
fied TGF-β, IL-10, and IL-8 as downregulated in all HCC cell 
lines following STAT3 targeting, while IFN-γ was consist-
ently upregulated. The importance of TGF-β in regulating 
NK-mediated tumor killing was demonstrated by increased 
HCC cell lysis following anti-TGF-β treatment. Conversely, 
increased NK-mediated tumor cell killing conferred by 
STAT3 decoy oligonucleotide was reversed by the addition 
of exogenous TGF-β. The immunotherapeutic potential of 
blocking TGF-β has been suggested by some recent studies in 
preclinical models. Alvarez et  al. showed that a neutralizing 
anti-TGF-β antibody could reverse NK inhibition within the 
tumor microenvironment in the murine Lewis lung carcinoma 
(LLC) model of NSCLC (194).
NK CeLL ReGULATiON BY eNDOGeNOUS 
FeeDBACK iNHiBiTORS OF STAT3
Tumor cells become addicted to STAT3 signaling via the constitu-
tive expression of STAT3-activating growth factors and cytokines 
or constitutively active mutations of RTKs or cytoplasmic kinases. 
However, STAT3 dependence is often further driven by inactiva-
tion of endogenous negative feedback mechanisms that normally 
control STAT3 signaling. Among these mechanisms, the SOCS 
are a large superfamily of STAT inhibitors, some of which bind 
directly to activated kinases or receptor chains and blunt cytokine 
and growth factor-driven STAT activation (195–198). STAT3 
dependence in tumors is often accompanied by epigenetic silenc-
ing of the SOCS1 or SOCS3 genes via CpG island hypermethyla-
tion and histone deacetylation, which greatly enhances the cell’s 
sensitivity to STAT3 activation, increasing both the magnitude 
and duration of a STAT3-dependent stimulus. Selective pressure 
to repress SOCS3 expression in STAT3-addicted tumors has been 
shown in cancers of the brain, esophagus, prostate, lung, bone 
marrow, colon, liver, cervix, and head/neck (199–206), which 
suggests that SOCS3 inhibition may not only promote tumor cell 
proliferation and metastasis but also drive tumor cell-mediated 
immunosuppression.
Modulation of SOCS3 in tumor-infiltrating myeloid cells 
may also contribute to an immunosuppressive environment that 
represses NK activity. Yu et al. have recently shown that SOCS3-
deficient myeloid cells (SOCS3MyeKO) displayed enhanced STAT3 
phosphorylation and increased levels of IL-1, IL-6, TNF-α, and 
iNOS (207). SOCS3MyeKO bone marrow cells preferentially dif-
ferentiated into MDSC-like cells when cultured in conditioned 
medium from TRAMP-C1 prostate cancer cells, and TRAMP-C1 
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tumor growth was accelerated in SOCS3MyeKO compared to WT 
mice, indicating that SOCS3 can control the extent of MDSC 
production and may indirectly regulate NK activity in the tumor 
microenvironment.
In contrast, it has been shown that SOCS3 may drive the 
generation of immunosuppressive DCs. Mesenchymal stem/
stromal cells can induce HSCs to differentiate into CD11b+, 
Interleukin-10-dependent regulatory DCs (208). This novel 
differentiation pathway was highly dependent on IL-10-driven 
chromatin reorganization and activation of the SOCS3 locus and 
could be reversed by siRNA-mediated SOCS3 targeting. This 
study suggests that SOCS3 can contribute to an immunosuppres-
sive phenotype by skewing the DC developmental program in 
hematopoietic progenitors.
Analysis of SOCS3 in NK cells suggests that it may have a 
distinct, direct role in this lineage as well. Braunschweig et  al. 
demonstrated that SOCS3 can regulate NK cytolytic activity, 
using the NK-92 human NK cell line (209). Small interfering 
RNA-mediated targeting of SOCS3 resulted in increased STAT3 
phosphorylation and NK-mediated killing of tumor targets, 
which suggests that SOCS3 may be a negative regulator of NK 
activity and therapeutic targeting of SOCS3 in NK cells may 
potentiate killing of tumor targets.
Likewise, Xu et al. demonstrated that the chemokine CCL2 can 
inhibit NK cytolytic function by inducing SOCS3 and partially 
blocking perforin expression (210). CCL2 impaired the cytolytic 
activity of freshly isolated CD56+ human NK cells toward K562 
targets, which coincided with SOCS3 induction and partially 
repressed perforin expression. Transfection of a SOCS3-specific 
siRNA reversed both the perforin repression and inhibition of 
cytolytic activity.
Chemokines, such as CCL2, which are normally critical 
for NK migration and tumor elimination, can in fact become 
immunosuppressive in a tumor microenvironment lacking key 
NK-activating “costimulatory” cytokines. Without each compo-
nent of the process, CCL2 may repress NK activation through a 
SOCS3-dependent mechanism.
These findings suggest a dual role for SOCS3 in tumor 
immunity. On the one hand, when expressed in cancer cells and 
MDSC precursors, SOCS3 can promote antitumor immunity 
by blocking the effects of STAT3-inducing, immunosuppressive 
cytokines. On the other hand, in NK cells and DC precursors, 
SOCS3 may be a key mediator of STAT3-driven immunosup-
pression. The in vivo relevance of these observations will depend 
on the generation tissue-specific knockout animals with targeted 
SOCS3 deletion in DCs and NK cells.
The PIAS is another family of feedback inhibitors of STAT 
activation that are aberrantly modulated in tumors. It comprised 
four members: PIAS1, PIAS3, PIASx, and PIASy that can directly 
bind to STATs and block phosphorylation, DNA binding, and 
transactivation (211, 212); STAT3 is targeted primarily by the 
PIAS3 protein. While PIAS proteins can be overexpressed in 
some cancers (213), PIAS3 expression is repressed in anaplastic 
lymphoma, glioblastoma, mesothelioma, and NSCLC, which 
correlates to constitutive STAT3 activation (214–217). Thus, by 
promoting STAT3 activation, repression of PIAS3 expression 
in tumor cells can indirectly contribute to NK cell dysfunction 
by altering the cytokine profile of the cancer. In addition, some 
studies suggest that inactivation of PIAS3 may be involved in 
tumor-associated immunosuppression via IDO expression in 
chemoresistant cancers.
These studies suggest an important link between tumor- 
mediated immunosuppression and other, early events in 
tumorigenesis, especially epigenetic silencing of potential tumor 
suppressor genes. The role of SOCS3 as a negative feedback 
inhibitor of STAT3 signaling often targets it for CpG island 
methylation in cells that are addicted to STAT3 signaling and, 
as an additional selective advantage, may induce or enhance 
the immunosuppressive potential of STAT3-addicted tumors. 
Moreover, downregulation of SOCS3 in the myeloid compart-
ment can contribute to increased STAT3 phosphorylation, 
activation of a MDSC developmental pathway, and the secretion 
of immunosuppressive cytokines.
CONCLUSiON
The STAT3 transcription factor has been known for many years to 
drive tumorigenesis, cancer cell survival, proliferation, metastasis, 
and resistance to anticancer agents. Only relatively recently has its 
role in the immune system’s response to cancer been fully appreci-
ated. STAT3 regulates antitumor immunity at virtually every level, 
affecting both lymphoid and myeloid compartments, innate and 
adaptive immunity, effector cells and APCs, cell migration to the 
tumor microenvironment, cytolytic and helper function, and the 
secretion of cytokines and growth factors that modulate immune 
responses. NK cells are greatly affected by activated STAT3 both 
intrinsically and extrinsically. Hematopoietic and NK-specific 
STAT3 genetic ablation have demonstrated that STAT3 is not 
critical for normal NK development or proliferation. However, 
STAT3 negatively regulates NK activation and tumor cell killing, 
as STAT3-deficient NK cells generally exhibit enhanced cytolytic 
activity and cytokine secretion in vitro and in vivo. The molecular 
basis of this regulation is not well understood, although it likely 
involves STAT3-mediated repression of NK activating receptors, 
such as DNAM-1, as well as cytolytic mediators, such as perforin 
and granzyme B.
Aside from the direct effects of STAT3 activation in NK 
cells, constitutive STAT3 phosphorylation in transformed cells 
can indirectly impair NK function by regulating the expres-
sion of ligands for NK activating receptors as well as important 
immune checkpoint proteins. For example, tumors can escape 
NK-mediated recognition and lysis through STAT3-dependent 
downregulation of the NKG2D ligand MICA. This is likely to 
impair a critical mechanism to eliminate tumor cells that have 
been treated with DNA damaging agents such as radiation. 
Likewise, STAT3-driven PD-L1 expression in tumor cells may 
dampen antitumor immunity by engaging the PD-1 receptor on 
the surface of NK cells.
Perhaps more importantly, STAT3 activation in tumor cells 
triggers a cascade of cytokine and growth factor production 
that reprograms the tumor microenvironment, skewing it 
toward immunosuppression. Cytokines produced by tumor cells 
activate STAT3 in NK cells, DCs, T cells, and macrophages that 
profoundly affect each population intrinsically and via critical 
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crosstalk mechanisms that shut down both innate and adaptive 
immunity. STAT3 activation in DCs results in impaired IL-12 
production, leading to defective NK activation and reduced 
cytolytic activity toward tumor targets as well as tolerogenic, 
immature DCs. Reciprocally, poorly activated NK cells fail to 
produce critical cytokines (IFN-γ and TNF-α) to DCs and T cells, 
which impairs DC maturation, antigen presentation, and T cell 
activation. Likewise, STAT3 activation in macrophages alters the 
balance between IL-12 and IL-23, which enhances carcinogenesis 
and impairs NK function. This complex web of inhibitory interac-
tions between tumor cells and components of innate and adaptive 
immunity can send the immune system into a downward spiral 
in the tumor microenvironment. Finally, STAT3 activation in 
tumor cells impairs the migration of virtually every component 
of the immune response to the tumor microenvironment, such 
that responding cells cannot reach the site of the cancer; target-
ing STAT3 in tumors alters their cytokine/growth factor profile, 
resulting in increased migration to microenvironment and 
potentially enhancing antigen presentation and immune effector 
functions.
The role of STAT3 in anticancer immunity and therapy 
becomes even more complex in light of studies suggesting that 
STAT3 can promote NK-mediated tumor immunity. Some 
reports have shown that STAT3 can increase the expression of 
the NK activating receptor NKG2D and promote NK-mediated 
immunosurveillance in some lymphoma models. Thus, biological 
targeting of STAT3 in tumor cells may not only have synergistic 
effects by potentiating the function of NK cells and other com-
ponents of the immune response but also produce inhibitory 
off-target effects on NK cells in certain cancers. This raises the 
possibility that STAT3 inhibitors may work best when combined 
with one or more of the novel, potent immune checkpoint 
inhibitors that target PD-1, PD-L1, or CTLA-4, inhibition of 
immunosuppressive factors, such as IDO, or treatment with 
chromatin modifiers that release SOCS genes from epigenetic 
repression in tumor cells. Molecular profiling of tumor tissue, as 
well as infiltrating lymphoid and myeloid cells, may be of great 
value to predict the possible immunologic outcome of treating 
cancer patients with STAT3 inhibitors.
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